Bright Minds Biosciences Announces Resignation of Board Member

Rhea-AI Summary

Bright Minds Biosciences (BMB) announced the resignation of Dr. Doug Williamson from its Board of Directors as he transitions to a new full-time role. Dr. Williamson's contributions during his brief tenure were acknowledged for their value in advancing the company's mission to develop innovative treatments for neuropsychiatric disorders, including resistant epilepsy and treatment-resistant depression.

CEO Ian McDonald expressed gratitude for Dr. Williamson's service and commitment to enhancing patient lives through novel therapeutics, highlighting the company's focus on developing next-generation drugs with improved efficacy and reduced side effects.

Positive

• Dr. Doug Williamson's expertise supported the company's drug development efforts.
• Focus on innovative treatments for complex neuropsychiatric disorders.

Negative

• Concerns about continuity in Board expertise following Dr. Williamson's resignation.

VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Dr. Doug Williamson has resigned from its Board of Directors. Dr. Williamson has accepted a new full-time role that precludes his participation on the Bright Minds Board.

“In his short tenure on the Board, Doug’s scientific, clinical, and medical experience has proven invaluable in supporting our efforts to develop the next generation of safe and efficacious drugs for challenging brain disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. We wish him well in his new endeavors,” stated Ian McDonald, CEO and Co-founder of Bright Minds Biosciences.

“It has been an honor to serve on the Bright Minds Board. While I am stepping down from this role, I look forward to following the Company’s future progress as it works to create novel therapeutics to improve patient lives,” said Dr. Doug Williamson.

About Bright Minds

Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The Company leverages its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds’ drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Investor Contact:
Lisa Wilson
E: lwilson@insitecony.com
T: 917-543-9932

Ian McDonald
CEO and Director
E: ian@brightmindsbio.com
T: 647 407 2515

FAQ

What impact does Dr. Doug Williamson’s resignation have on Bright Minds Biosciences (BMB)?

Dr. Williamson's resignation may impact the continuity of expertise on the Board, though his contributions were valued during his tenure.

Why did Dr. Doug Williamson resign from Bright Minds' Board of Directors?

Dr. Williamson resigned to accept a full-time role that precludes his participation on the Board.

What is Bright Minds Biosciences focused on developing?

Bright Minds is focused on creating novel drugs for neuropsychiatric disorders, epilepsy, and pain management.

What are the main therapeutic areas Bright Minds is targeting?

The company is targeting resistant epilepsy, treatment-resistant depression, PTSD, and pain through next-generation therapeutics.